BofA is Bullish on CRISPR Therapeutics AG (CRSP)

On January 22, 2026, TheFly disclosed that Alec Stranahan, a BofA analyst. It reduced the terms nonsubjective for CRISPR Therapeutics AG (NASDAQ:CRSP) from $90 to $89 and retained a bargain rating. Casgevy’s 2026 projections were somewhat lowered arsenic a effect of the modification. Based connected an net preview insubstantial covering the biotechnology group, BofA inactive projects consecutive betterment for Casgevy done 2026 contempt the change.

CRISPR Therapeutics AG (NASDAQ:CRSP) separately announced its planned 2026 milestones and strategical priorities connected January 12, 2026. As per the company, Casgevy is gaining traction, and quarterly updates and ongoing worldwide commercialization are anticipated. It is projected that Casgevy regulatory submissions for patients aged 5 to 11 volition commencement successful the archetypal fractional of 2026. According to the firm, further important events see the Lp(a) programme successful 2026 and advancements from CTX310. Furthermore, it includes autoimmune and immuno-oncology updates for zugocabtagene geleucel, arsenic good arsenic top-line Phase 2 information from CTX611 successful the 2nd fractional of 2026. Additionally, the advancements see the planned commencement of objective trials for CTX460 successful the mediate of 2026 and CTX340 successful the archetypal fractional of 2026.

CRISPR Therapeutics AG (NASDAQ:CRSP) is simply a cistron editing firm.

While we admit the imaginable of CRSP arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 20 Best Performing Stocks successful 2025 and 12 Best Food Stocks to Buy successful 2026. 

Disclosure: None. This nonfiction is primitively published at Insider Monkey.